Meanwhile, in the BROCADE3 trial, HER2- BC patients with gBRCAm were treated with veliparib and chemotherapy, followed by maintenance treatment with veliparib, and compared against HER2- BC patients who were subjected to chemotherapy and a placebo. The gene discussed is ERBB2; the disease is breast cancer.